Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akanda Corp. stock logo
AKAN
Akanda
$1.41
+4.4%
$1.28
$0.93
$5.08
$2.02M1.6196,390 shs71,208 shs
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
$4.22
+53.5%
$1.34
$0.64
$4.31
$11.33M0.31673,504 shs1.97 million shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.53
-6.6%
$0.72
$0.25
$4.71
$7.55M1.382.45 million shs3.36 million shs
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
$9.00
-1.4%
$8.21
$6.15
$905.52
$7.47M1.4103,955 shs29,545 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akanda Corp. stock logo
AKAN
Akanda
-4.93%+3.85%-7.85%+26.17%-70.00%
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
+8.70%+36.14%+119.79%+143.36%+22.22%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
+9.70%+64.60%-14.63%-21.76%-82.40%
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
-1.30%+10.13%+21.73%-18.20%-99.96%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akanda Corp. stock logo
AKAN
Akanda
0.5837 of 5 stars
0.03.00.00.00.81.70.6
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
0.902 of 5 stars
0.05.00.00.02.30.80.0
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
3.0837 of 5 stars
3.52.00.00.03.11.71.3
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
2.0648 of 5 stars
3.54.00.00.00.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akanda Corp. stock logo
AKAN
Akanda
0.00
N/AN/AN/A
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
0.00
N/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
3.00
Buy$4.00649.06% Upside
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
3.00
Buy$280.003,011.11% Upside

Current Analyst Ratings Breakdown

Latest AKAN, LIXT, RNAZ, and MBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
6/9/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$4.00
4/16/2025
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$560.00 ➝ $280.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akanda Corp. stock logo
AKAN
Akanda
$840K2.40N/AN/A$3.00 per share0.47
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
N/AN/AN/AN/A($1.19) per shareN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/A$1.77 per shareN/A
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/AN/AN/AN/A($54.96) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akanda Corp. stock logo
AKAN
Akanda
-$4.10MN/A0.00N/AN/AN/AN/AN/A
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
-$3.59M-$1.45N/AN/AN/AN/A-189.35%8/6/2025 (Estimated)
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$21.76MN/A0.00N/AN/AN/A-278.80%-100.11%8/4/2025 (Estimated)
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
-$16.75MN/A0.00N/AN/AN/A-578.88%-222.61%N/A

Latest AKAN, LIXT, RNAZ, and MBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q4 2024
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
-$2.00-$0.60+$1.40-$2.51$0.30 millionN/A
5/13/2025Q1 2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$0.71-$0.69+$0.02-$0.69N/AN/A
5/12/2025Q1 2025
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
N/A-$0.29N/A-$0.29N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akanda Corp. stock logo
AKAN
Akanda
N/AN/AN/AN/AN/A
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
N/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/AN/A
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akanda Corp. stock logo
AKAN
Akanda
N/A
1.39
1.39
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
N/A
4.26
4.26
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/A
1.35
1.35
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/A
5.20
5.20

Institutional Ownership

CompanyInstitutional Ownership
Akanda Corp. stock logo
AKAN
Akanda
1.00%
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
5.10%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
15.52%
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Akanda Corp. stock logo
AKAN
Akanda
20.39%
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
14.80%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
1.90%
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
0.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akanda Corp. stock logo
AKAN
Akanda
1101.43 million1.14 millionNot Optionable
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
42.68 million2.29 millionNot Optionable
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2014.13 million13.86 millionNot Optionable
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
9830,000832,000Not Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akanda stock logo

Akanda NASDAQ:AKAN

$1.41 +0.06 (+4.44%)
Closing price 03:59 PM Eastern
Extended Trading
$1.42 +0.02 (+1.06%)
As of 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.

Lixte Biotechnology stock logo

Lixte Biotechnology NASDAQ:LIXT

$4.22 +1.47 (+53.45%)
Closing price 04:00 PM Eastern
Extended Trading
$4.05 -0.17 (-4.03%)
As of 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Moleculin Biotech stock logo

Moleculin Biotech NASDAQ:MBRX

$0.53 -0.04 (-6.64%)
Closing price 04:00 PM Eastern
Extended Trading
$0.54 +0.00 (+0.56%)
As of 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

TransCode Therapeutics stock logo

TransCode Therapeutics NASDAQ:RNAZ

$9.00 -0.13 (-1.42%)
Closing price 04:00 PM Eastern
Extended Trading
$8.96 -0.04 (-0.39%)
As of 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.